Compare Gilead Sciences, Inc. (GILD) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Zillow Group Inc Class A — how do they compare? Gilead Sciences, Inc. trades at $133.33 (market cap $163.51B), while Zillow Group Inc Class A trades at $33.97 (market cap $7.74B). The key difference: Gilead Sciences, Inc. is far larger — about 21.1× Zillow Group Inc Class A's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Zillow Group Inc Class A pays none. Which is the better fit depends on your goals.
| GILD | ZG | |
|---|---|---|
Market Cap | $163.51B | $7.74B |
Sector | Health | Media |
52-Week High | $155.80 | $86.76 |
52-Week Low | $108.22 | $29.14 |
Enterprise Value | $178.05B | $7.38B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zillow Group (ZG) trades at $31.80, down 0.44% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net income of $23 million in 2025, marking a return to profitability after losses in prior years, though valuation ratios like a P/E of 134.94 suggest high expectations. Recent news highlights multiple securities fraud class action lawsuits filed against the company, alleging anticompetitive practices, which has heightened investor scrutiny.
The outlook is mixed: analyst consensus is bullish with a $57.80 price target, but legal risks and a high P/E ratio pose significant headwinds. Revenue growth to $2.58 billion in 2025 and improving margins offer fundamental support, yet the stock faces pressure from ongoing litigation and volatile cash flows, requiring careful risk assessment for potential investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
